Shaheen and Capito lead bipartisan IMPACT law to reform drug retention period for opioid use disorder for providers

23 November 2021

(Washington, DC) – U.S. Senators Jeanne Shaheen (D-NH) and Shelley Moore Capito (R-WV) have introduced bipartisan legislation that would increase the length of time a doctor can hold long-acting injectable buprenorphine (LAI) – a form of medication for disorders related to the use of opioids – in a specialized pharmacy. U.S. Representatives Madeleine Dean (PA-04), Victoria Spartz (IN-05), Mary Gay Scanlon (PA-05) and Brian Fitzpatrick (PA-01) led the complementary legislation to the IMPACT Act in the House of Representatives.

The current 14 day window is a barrier for healthcare providers using buprenorphine LAI due to the logistical hurdles associated with specialty pharmacy delivery. This legislation reforms the law envisaged in the SUPPORT law by allowing health care providers to keep the drug in their establishment for up to 60 days. It helps facilitate continuity of care and treatment for Americans with opioid use disorders by reducing an unnecessary barrier to this innovative treatment method.

“The substance use disorder epidemic was a crisis in our communities before COVID-19 hit, but after two years of battling the pandemic we have seen one public health emergency exacerbate another with over 100,000 overdose deaths over a 12-month period. Now more than ever, we must ensure that nothing is overlooked in our response efforts to help those who are recovering, which is precisely what our bipartite and bicameral legislation would help us achieve ”, said Senator Shaheen. “Drug-assisted treatment is part of our multi-faceted strategy to tackle the crisis of substance use disorders, and our legislation is carrying out common-sense reform to improve access so providers can deliver. urgently needed treatment for people with drug addiction. “

“The most recent data on overdose deaths from the CDC is another sign that we need to redouble our efforts to tackle the drug abuse crisis,” said Senator Capito. “In addition to preventing addiction before it starts and stopping the flow of drugs into our communities, treatment is a critical part of this fight. The bipartisan bill that Senator Shaheen and I are drafting would support those struggling with the disease of addiction by increasing access to mediated treatment and better equipping medical providers to help them on the way. recovery.

This bill is supported by the American Society of Addiction Medicine, American Psychiatric Association, American Medical Association, Advocates for Opioid Recovery, Aimed Alliance, Association of Nurses in AIDS Care, Center for US Policy, FORCE, Kennedy Forum, Maryland Heroin Awareness, Mother’s Addiction Journey, No More OD’s Inc., Partnership to End Addiction, Prevention Action Alliance, Shatterproof, The Voices Project, Tyler’s Light, and Young People in Recovery.

The text of the invoice is available here.

Following reports that the manufacturer of buprenorphine, which is used to treat people with disorders related to the use of opioid-related substances in drug-assisted therapy (MAT), was trying to ‘To use the orphan drug approval process to gain an additional seven years of exclusivity and block potentially cheaper generic versions of the drug from appearing on the market, Shaheen sent a letter to the FDA calling on the agency to prevent the drug from appearing on the market. manufacturer to abuse the system. Following Shaheen’s actions, the FDA revoked the orphan drug status of buprenorphine.


Previous article

About Rhonda Lee

Check Also

Exec Farrow of Waukesha County: Waukesha County Focuses on Schools and Crisis Response During National Awareness Week

(Waukesha, Wis.) – This National Prevention Week, Waukesha County leaders announce new efforts to prevent …